A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/455 (2006.01) A01N 61/00 (2006.01) A61K 31/33 (2006.01) A61K 31/4196 (2006.01) A61K 31/427 (2006.01) A61K 31/429 (2006.01) A61K 31/4439 (2006.01) A01N 33/26 (2006.01) A01N 43/00 (2006.01) A01N 43/04 (2006.01) A01N 45/00 (2006.01) A61K 31/00 (2006.01) A61K 31/655 (2006.01) A61K 31/70 (2006.01)
Patent
CA 2274604
The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4+ T cell immune responses by identifying compounds that block the interaction of CD4 and class II MHC gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4+ T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 500 and 150 daltons that bind to the GFCC'C'' portion of the D1 domain of human CD4 lymphocyte cell surface antigen.
L'invention concerne un procédé pour identifier des composés pouvant être utilisés pour inhiber des réactions immunitaires indésirables de lymphocytes CD4?+¿T chez l'homme, par identification de composés qui bloquent l'interaction de CD4 avec des produits géniques HLA de classe II. L'invention concerne également une méthode de traitement consistant à administrer un tel composé identifié. Ces composés qui inhibent des réactions immunitaires indésirables chez l'homme, provoquées par les lymphocytes CD4?+¿T, peuvent être utilisés pour traiter des maladies telles que la sclérose en plaques, et pour empêcher les rejets de greffes et la réaction du greffon contre l'hôte. L'invention concerne plus particulièrement des composants présentant un poids moléculaire compris entre environ 500 et 150 daltons, qui se lient à la partie GFCC'C'' du domaine D1 de l'antigène de surface du lymphocyte CD4 chez l'homme.
Huang Ziwei
Korngold Robert
Gowling Lafleur Henderson Llp
Thomas Jefferson University
LandOfFree
The use of cd4-binding small molecules to inhibit immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with The use of cd4-binding small molecules to inhibit immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and The use of cd4-binding small molecules to inhibit immune... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2068913